GSEP
DNLI icon

Golden State Equity Partners’s Denali Therapeutics DNLI Stock Holding History

Golden State Equity Partners’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-130
Closed -$2.5K – 702
2026
Q1 		$2.5K Buy
+130
New +$2.59K ﹤0.01% 1621

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Golden State Equity Partners's DNLI Position: Q2 2026 in Review

Golden State Equity Partners sold out of Denali Therapeutics (DNLI) in Q2 2026, closing a stake of 130 shares — an estimated $2.5K sold.

Golden State Equity Partners first reported a position in DNLI in Q1 2026 and held it in 1 quarter. The position peaked at $2.5K in Q1 2026. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Golden State Equity Partners reported no remaining Denali Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 130 Denali Therapeutics shares in Q2 2026, an estimated $2.5K.
  • Golden State Equity Partners first reported a position in Denali Therapeutics in Q1 2026 and held it in 1 quarter.
  • Golden State Equity Partners's Denali Therapeutics position peaked at $2.5K in Q1 2026.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.